- Market Capitalization, $K 31,750
- Shares Outstanding, K 5,032
- Annual Sales, $ 53,940 K
- Annual Income, $ -10,440 K
- 60-Month Beta 2.20
- Price/Sales 0.64
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
+0.59 (+10.31%)since 07/07/20
| || |
+0.49 (+8.42%)since 05/07/20
| || |
-1.79 (-22.10%)since 08/07/19
A recent report provides crucial insights along with application based and forecast information in the Global Ocular Inflammation Treatment Market. The report provides a comprehensive analysis of key factors...
Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.
AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.
ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.
Horizon Therapeutics' (HZNP) earnings decline year over year and sales beat estimates in the second quarter of 2020.
Zoetis (ZTS) beats both earnings and sales estimates in the second quarter of 2020.
Alimera Sciences (ALIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 76.17% and 336.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
ALPHARETTA, Ga. (AP) _ Alimera Sciences Inc. (ALIM) on Wednesday reported a loss of $2.5 million in its second quarter.